PapersFlow Research Brief
Protein Tyrosine Phosphatases
Research Guide
What is Protein Tyrosine Phosphatases?
Protein tyrosine phosphatases are enzymes that remove phosphate groups from tyrosine residues on proteins, thereby negatively regulating tyrosine kinase signaling pathways in cellular processes.
The field encompasses 35,370 papers focused on protein tyrosine phosphatases such as PTEN and PTPN11 (also known as SHP2) in human health and disease, including Noonan syndrome, cancer, insulin sensitivity, and MAP kinase signaling. PTEN functions as a lipid phosphatase that dephosphorylates phosphatidylinositol 3,4,5-trisphosphate, acting as a tumor suppressor mutated in cancers like glioblastoma, breast, and prostate. Redox regulation and mutations in these phosphatases influence cell signaling pathways critical for growth, survival, and oncogenesis.
Topic Hierarchy
Research Sub-Topics
PTPN11 Mutations in Noonan Syndrome
This sub-topic examines the genetic mutations in PTPN11 encoding SHP2 phosphatase and their causal role in Noonan syndrome pathogenesis. Researchers study genotype-phenotype correlations, signaling dysregulation, and therapeutic targeting of mutant SHP2.
SHP2 in RAS-MAPK Signaling
This area investigates SHP2's scaffolding and catalytic roles in activating RAS-MAPK pathways downstream of receptor tyrosine kinases. Studies focus on allosteric regulation, inhibitor development, and pathway crosstalk in development and disease.
Redox Regulation of PTPs
Researchers explore oxidative inactivation of PTP catalytic cysteines by hydrogen peroxide and physiological ROS, including recovery mechanisms via thioredoxin. This sub-topic covers implications for redox signaling in immunity, growth factor responses, and oxidative stress diseases.
PTPN11 in Oncogenic Signaling
This sub-topic analyzes gain-of-function PTPN11 mutations promoting leukemogenesis and solid tumors through sustained ERK activation. Research includes SHP2 allosteric inhibitors, combination therapies, and tumor microenvironment interactions.
PTPs in Insulin Signaling
Studies investigate negative regulation of insulin receptor signaling by PTP1B, TCPTP, and others, focusing on dephosphorylation kinetics, knockout models, and inhibitor screens for diabetes therapy. This includes tissue-specific roles in liver, muscle, and adipose.
Why It Matters
Protein tyrosine phosphatases like PTEN serve as tumor suppressors, with mutations detected in 31% (13/42) of glioblastoma cell lines, primary glioblastomas, as well as breast, prostate, and other advanced cancers, highlighting their role in cancer suppression (Li et al. (1997) "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer"; Steck et al. (1997) "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers"). PTEN dephosphorylates the lipid second messenger phosphatidylinositol 3,4,5-trisphosphate, reducing insulin-induced levels in human 293 cells and counteracting growth signaling (Maehama and Dixon (1998) "The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate"). PTPN11/SHP2 mutations contribute to Noonan syndrome and cancers via dysregulated MAP kinase signaling, while broader impacts include regulation of insulin sensitivity and cell survival pathways intersecting with receptor tyrosine kinases.
Reading Guide
Where to Start
"PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer" by Li et al. (1997), because it introduces PTEN's discovery, mutation frequency in cancers (31% in glioblastomas), and foundational tumor suppressor role, providing essential context before deeper signaling mechanisms.
Key Papers Explained
Li et al. (1997) "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer" first isolated PTEN via 10q23 deletions, showing mutations in 31% of glioblastomas, establishing it as a phosphatase tumor suppressor; Steck et al. (1997) "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers" confirmed MMAC1/PTEN mutations across cancers, reinforcing its broad role; Maehama and Dixon (1998) "The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate" mechanistically linked PTEN to lipid dephosphorylation, explaining growth suppression via PtdIns(3,4,5)P3 reduction. Schlessinger (2000) "Cell Signaling by Receptor Tyrosine Kinases" contextualizes PTEN's opposition to RTK signaling, while Heinrich et al. (2003) "Principles of interleukin (IL)-6-type cytokine signalling and its regulation" extends to cytokine-phosphatase crosstalk.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research emphasizes PTPN11/SHP2 in Noonan syndrome, cancer, and insulin signaling, with focus on redox regulation of phosphatases in oxidative environments. No recent preprints or news available, so frontiers remain in mapping PTPN11 mutations' quantitative effects on MAP kinase and unexplored phosphatase-receptor interactions from the core cluster.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Akt Promotes Cell Survival by Phosphorylating and Inhibiting a... | 1999 | Cell | 6.5K | ✓ |
| 2 | A modified uronic acid carbazole reaction | 1962 | Analytical Biochemistry | 6.2K | ✕ |
| 3 | Rho GTPases and the Actin Cytoskeleton | 1998 | Science | 6.1K | ✕ |
| 4 | <i>PTEN</i> , a Putative Protein Tyrosine Phosphatase Gene Mut... | 1997 | Science | 4.8K | ✕ |
| 5 | STATs and Gene Regulation | 1997 | Science | 4.0K | ✕ |
| 6 | Cell Signaling by Receptor Tyrosine Kinases | 2000 | Cell | 3.7K | ✓ |
| 7 | Principles of interleukin (IL)-6-type cytokine signalling and ... | 2003 | Biochemical Journal | 3.2K | ✓ |
| 8 | The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid S... | 1998 | Journal of Biological ... | 3.1K | ✓ |
| 9 | Identification of a candidate tumour suppressor gene, MMAC1, a... | 1997 | Nature Genetics | 2.8K | ✕ |
| 10 | A synthetic inhibitor of the mitogen-activated protein kinase ... | 1995 | Proceedings of the Nat... | 2.7K | ✓ |
Frequently Asked Questions
What is the function of PTEN as a protein tyrosine phosphatase?
PTEN is a tumor suppressor that dephosphorylates phosphatidylinositol 3,4,5-trisphosphate, a key lipid second messenger in cell growth signaling. Overexpression of PTEN reduces insulin-induced PtdIns(3,4,5)P3 production in human 293 cells. This activity positions PTEN as a regulator of phosphoinositide signaling in cancer suppression (Maehama and Dixon (1998) "The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate").
How frequently is PTEN mutated in human cancers?
Mutations of PTEN were detected in 31% (13/42) of glioblastoma cell lines and primary glioblastomas, as well as in brain, breast, and prostate cancers. Homozygous deletions on chromosome 10q23 led to the isolation of PTEN as a candidate tumor suppressor mutated at considerable frequency across multiple cancer types. These findings underscore PTEN's role in tumor suppression (Li et al. (1997) "PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer").
What role do protein tyrosine phosphatases play in cell signaling?
Protein tyrosine phosphatases counterbalance receptor tyrosine kinases by dephosphorylating tyrosine residues, modulating pathways like MAP kinase signaling. They integrate with cascades involving STATs, IL-6-type cytokines, and lipid messengers. Dysregulation contributes to diseases including cancer and insulin resistance (Schlessinger (2000) "Cell Signaling by Receptor Tyrosine Kinases"; Heinrich et al. (2003) "Principles of interleukin (IL)-6-type cytokine signalling and its regulation").
Which protein tyrosine phosphatases are implicated in cancer?
PTEN (MMAC1) is mutated in glioblastoma, breast, prostate, and advanced cancers at chromosome 10q23.3. PTPN11/SHP2 mutations link to Noonan syndrome and oncogenesis via MAP kinase dysregulation. These phosphatases act as tumor suppressors by inhibiting growth signals (Steck et al. (1997) "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers").
What is the connection between PTPN11 and disease?
PTPN11, also known as SHP2, is a protein tyrosine phosphatase involved in Noonan syndrome through gain-of-function mutations. It regulates MAP kinase signaling and is implicated in cancers and insulin sensitivity. Cluster analysis shows PTPN11's central role in these pathologies.
Open Research Questions
- ? How do redox modifications specifically regulate the catalytic activity of PTPN11/SHP2 in oxidative stress conditions?
- ? What are the precise structural mechanisms by which PTEN mutations at 10q23 impair its lipid phosphatase function in diverse cancers?
- ? In what ways do PTPN11 mutations quantitatively alter MAP kinase signaling thresholds in Noonan syndrome and leukemogenesis?
- ? How do protein tyrosine phosphatases integrate with receptor tyrosine kinase pathways to fine-tune insulin sensitivity?
- ? What undiscovered phosphatase substrates drive cell survival dysregulation in PTEN-deficient tumors?
Recent Trends
The field maintains 35,370 works with sustained interest in PTPN11/SHP2 roles in Noonan syndrome, cancer via MAP kinase, and insulin sensitivity, as per cluster data.
No growth rate available over 5 years, and no recent preprints or news in the last 6-12 months indicate steady rather than accelerating publication trends.
Research Protein Tyrosine Phosphatases with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Protein Tyrosine Phosphatases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers